Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Clinica Universidad de Navarra, Universidad de Navarra
Canadian Cancer Trials Group
Fudan University
SWOG Cancer Research Network
Tempus AI
Rigshospitalet, Denmark
North Eastern German Society of Gynaecological Oncology
AstraZeneca
BioCorteX Inc
Hoosier Cancer Research Network
Eastern Cooperative Oncology Group
AstraZeneca
AstraZeneca
Consorzio Oncotech
Sanjay Gandhi Postgraduate Institute of Medical Sciences
University of Zurich
University of Minnesota
Association Européenne de Recherche en Oncologie